Health Care [ 10/12 ] | Biotechnology [ 38/73 ]
NASDAQ | Common Stock
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia.
The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 14, 25 | -0.43 Increased by +60.55% | -0.90 Increased by +52.22% |
| May 13, 25 | -0.50 Increased by +55.75% | -1.07 Increased by +53.27% |
| Feb 25, 25 | -0.56 Increased by +59.71% | -1.05 Increased by +46.67% |
| Nov 5, 24 | 2.97 Increased by +388.35% | -1.01 Increased by +394.06% |
| Aug 6, 24 | -1.09 Increased by +2.68% | -0.97 Decreased by -12.37% |
| May 1, 24 | -1.13 Increased by +13.74% | -1.20 Increased by +5.83% |
| Feb 22, 24 | -1.39 Decreased by -10.32% | -0.88 Decreased by -57.95% |
| Nov 7, 23 | -1.03 Increased by +20.16% | -0.77 Decreased by -33.77% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -3.26 M Increased by +60.42% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 42.22 K Increased by +N/A% | -3.75 M Increased by +56.20% | Decreased by -8.89 K% Decreased by N/A% |
| Dec 31, 24 | 42.22 K Increased by +N/A% | -4.27 M Increased by +52.65% | Decreased by -10.12 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | 22.51 M Increased by +387.89% | Increased by +N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -8.23 M Decreased by -32.96% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -8.57 M Decreased by -22.94% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -9.02 M Decreased by -34.14% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -7.82 M Decreased by -13.33% | Decreased by N/A% Decreased by N/A% |